Gene therapy in diabetes: A review of case study conducted over mice to cure type 2 diabetes and obesity
Keywords:
Diabetes, Gene therapy, ectopic expression, islet modificationAbstract
Type 1 diabetes “(T1D) is characterized by the destruction of insulin-secreting beta cells in the pancreas, which results in insulin insufficiency and hyperglycemia. If they don't have daily insulin injections, these patients will die from diabetic ketoacidosis (DKA). T1D patients may benefit from a variety of gene therapy techniques, including viral vector and non-viral transduction, such as decreasing autoreactive T cells to minimize islet death (prophylactic) or substituting the insulin gene for patients (post-disease). The lack of cadaveric islets for transplantation and the associated immunosuppression necessitated the development of a novel strategy for attaining euglycemia. Despite extensive research on insulin ectopic expression and islet modification, no cure has yet to be discovered. In the treatment of Type 1 Diabetes (T1D)”, numerous gene transfer techniques and a range of gene therapy procedures have been used, as well as possible novel treatments.
References
Klein R. Diabetic retinopathy. Annu Rev Public Health. 1996;17:137–158.
Sowers JR, Epstein M. Diabetes mellitus and associated hypertension, vascular disease and nephropathy. An update. Hypertension. 1995;26:869–879.
Vinik AI, Maser RE, Mitchell BD, Freeman R. Diabetic autonomic neuropathy. Diabetes Care. 2003;26:1553–1579.
McCulloch D. Classification of diabetes mellitus and genetic diabetic syndromes. In: Rose B, editor. UpToDate. Waltham, MA: UpToDate; 2007.
Glaser B. Type 2 diabetes: hypoinsulinism, hyperinsulinism or both? PLoS Med. 2007;4:148.
Lernmark A, Barmeier H, Dube S, Hagopian W, Karlsen AE, Markholst H, et al. Molecular analysis of the pathogenesis of beta-cell destruction in insulin-dependent diabetes mellitus. West J Med. 1990;153:499–502.
Harris MI, Robbins DC. Prevalence of adult-onset IDDM in the U.S. population. Diabetes Care. 1994;17:1337–1340.
Landin-Olsson M, Nilsson KO, Lernmark A, Sundkvist G. Islet cell antibodies and fasting C-peptide predict insulin requirement at diagnosis of diabetes mellitus. Diabetologia. 1990;33:561–568.
Niskanen LK, Tuomi T, Karjalainen J, Groop LC, Uusitupa MI. GAD antibodies in NIDDM. Ten-year follow-up from the diagnosis. Diabetes Care. 1995;18:1557–1565.
Chong JW, Craig ME, Cameron FJ, Clarke CF, Rodda CP, Donath SM, et al. Marked increase in type 1 diabetes mellitus incidence in children aged 0–14 yr in Victoria, Australia from 1999 to 2002. Pediatr Diabetes. 2007;8:67–73.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2022 International Journal for Research Publication and Seminar
This work is licensed under a Creative Commons Attribution 4.0 International License.
Re-users must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use. This license allows for redistribution, commercial and non-commercial, as long as the original work is properly credited.
